Nomlabofusp

Phase 1Small molecule

LLarimar Therapeutics, Inc.

Nomlabofusp is one of 42 small molecule programs targeting Friedreich ataxia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Friedreich AtaxiaTerminated

AtaxiaActive, not recruiting

Friedreich AtaxiaPhase 1

Terminated

AtaxiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Ataxia

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Approved

1 2

Plavix

Sanofi

Phase 3

1 3

Actos

Takeda

Phase 3

1 4

Bayer Aspirin

Bayer

Phase 3

1 5

Diamox

Teva

Phase 3

1 6

Chantix

PPrism Pharmaceuticals

Phase 3

1 7

Skyclarys

Biogen

Phase 2

4 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2

1 9

Ferriprox

Chiesi Farmaceutici S.p.A.

Phase 2

2 10

Decadron

AAspen Global Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Friedreich ataxia1 trial

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

Terminated·LLarimar Therapeutics, Inc.·Phase 1·NCT06681766·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nomlabofusp. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nomlabofusp compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nomlabofusp. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Larimar Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLarimar Therapeutics, Inc.

Nomlabofusp

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Friedreich ataxia1 trial

References

Drug Info

Quick Facts

Related News